Rabia Gurses Ozden

Rabia Gurses Ozden, M.D. joined Adverum’s board in March 2022. Dr. Ozden brings 20 years of experience in ophthalmology, clinical development and operations, pharmacovigilance, regulatory affairs and gene therapy. She currently serves as the senior vice president of clinical development at Ocular Therapeutix, a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye. Prior to joining Ocular Therapeutix, Dr. Ozden served as the chief development officer at Akouos, leveraging their adeno-associated virus (AAV)-based gene therapy platform to advance precision therapies for forms of sensorineural hearing loss. Prior to joining Akouos, Dr. Ozden served as the chief medical officer at Nightstar Therapeutics, an ocular gene therapy company focused on AAV treatments for inherited retinal diseases, which was acquired by Biogen in 2019. Additionally, Dr. Ozden has held leadership positions at Applied Genetic Technologies and GlaxoSmithKline, while spending her early career in clinical development roles. Dr. Ozden earned her M.D. from Hacettepe University School of Medicine, completed her ophthalmology residency at Ankara University School of Medicine, and her clinical